Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance

SIMPLE SUMMARY: Potential application of CDK12/13 inhibitor in overcoming resistance to osimertinib, a third-generation EGFR TKI, in vitro and in vivo. ABSTRACT: Osimertinib is a third-generation epidermal growth factor receptor and tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Maity, Tapan K., Kim, Eun Young, Cultraro, Constance M., Venugopalan, Abhilash, Khare, Leena, Poddutoori, Ramulu, Marappan, Sivapriya, Syed, Samiulla D., Telford, William G., Samajdar, Susanta, Ramachandra, Murali, Guha, Udayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137182/
https://www.ncbi.nlm.nih.gov/pubmed/37190191
http://dx.doi.org/10.3390/cancers15082263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137182/
https://www.ncbi.nlm.nih.gov/pubmed/37190191
http://dx.doi.org/10.3390/cancers15082263

Ejemplares similares